valsartan has been researched along with Chronic Kidney Failure in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 22 (52.38) | 29.6817 |
| 2010's | 13 (30.95) | 24.3611 |
| 2020's | 5 (11.90) | 2.80 |
| Authors | Studies |
|---|---|
| Di, X; Fu, L; He, Y; Jin, Y; Liu, R; Qi, X; Wang, Y; Wang, Z; Zheng, L; Zhong, H | 1 |
| Slomski, A | 1 |
| Agostoni, P; Cimino, R; Ferrari, C; Mantegazza, V; Mapelli, M; Maragna, R; Pepi, M; Pontone, G | 1 |
| Chen, Y; Han, X; Liu, J; Ma, Y; Xie, D; Xu, H | 1 |
| Heyse, A; Mahieu, E; Manhaeghe, L; Van Durme, F; Vanfraechem, C | 1 |
| Daimon, S; Maeda, K; Yasuda, M | 1 |
| Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S | 1 |
| Chen, XM; Huang, MJ; Li, P; Su, TY; Wang, Y; Wei, RB; Yang, Y | 1 |
| Bian, A; Brown, NJ; Davies, S; Dikalova, A; Fogo, AF; Gamboa, JL; Ikizler, TA; Kaseda, R; Kon, V; Linton, MF; Tsuchida, Y; Yang, H; Zhang, L; Zhong, J | 1 |
| Choovichian, P; Leelasiri, K; Satirapoj, B; Supasyndh, O | 1 |
| Baigent, C; Haynes, R; Judge, P; Landray, MJ | 1 |
| Brown, NJ; Gamboa, JL; Ikizler, TA; Pretorius, M; Sprinkel, KC | 1 |
| Bethel, MA; Currie, G; Haffner, SM; Holman, RR; Holzhauer, B; McMurray, JJV | 1 |
| Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T | 1 |
| Galle, J | 1 |
| Araki, R; Ikeda, N; Inoue, T; Kanno, Y; Shoda, J; Sugahara, S; Suzuki, H; Takenaka, T | 1 |
| Azuma, K; Dejima, T; Ishigami, T; Kokuho, T; Masuda, S; Mitsuhashi, H; Okano, Y; Ozawa, M; Shigenaga, A; Sugano, T; Tamura, K; Tokita, Y; Toya, Y; Tsurumi-Ikeya, Y; Uchino, K; Umemura, S; Wakui, H | 1 |
| Furuyama, M; Hashimoto, T; Hayasaka, K; Matsunaga, A; Ogino, D; Toyoda, K | 1 |
| Ecder, T; Kashihara, N; Locatelli, F; Palmer, BF | 1 |
| Choi, KH; Han, DS; Han, SH; Kang, EW; Kang, SW; Lee, HC; Yoo, TH; Yoon, HS; Yoon, SJ | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Brown, NJ; Gamboa, JL; Ikizler, TA; Luther, JM; Pretorius, M; Todd-Tzanetos, DR; Yu, C | 1 |
| Bassi, R; Caldara, R; De Cobelli, F; Del Maschio, A; Fiorina, P; Gremizzi, C; Mello, A; Perseghin, G; Secchi, A; Vergani, A | 1 |
| Chen, Z; Li, CC; Liu, X; Lou, T; Peng, H; Wang, C; Ye, ZC; Zhang, J | 1 |
| Krum, H; Martin, J | 1 |
| Kanno, Y; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H | 1 |
| Cooper, ME; Thomas, MC | 1 |
| Delcroix, C; Ekhlas, A; Esnault, VL; Moutel, MG; Nguyen, JM | 1 |
| Dilek, I; Dogan, E; Durmus, A; Erkoc, R; Sayarlioglu, H; Topal, C | 1 |
| Iigaya, K; Kumagai, H; Onami, T; Saruta, T; Takimoto, C | 1 |
| Averbukh, Z; Berman, S; Efrati, S; Galperin, E; Malcev, E; Manevits, E; Rosenberg, R; Weissgarten, J | 1 |
| Aslam, S; Leone, A; Santha, T; Wilcox, C | 1 |
| Zoccali, C | 1 |
| Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kondo, T; Li, L; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Ohno, T; Okada, H; Takemura, G | 1 |
| Acikel, C; Caglar, K; Cakir, E; Eyileten, T; Kurt, Y; Oguz, Y; Saglam, M; Sonmez, A; Tasar, M; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
| Bünten, B; Grabensee, B; Németh, R; Plum, J | 2 |
| Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM | 1 |
| Ganten, D; Geiger, H; Hartner, A; Hilgers, KF; Hugo, C; Mai, M; Mann, JF; Porst, M; Veelken, R; Wittmann, M | 1 |
| Coats, AJ | 1 |
| Kozlovskaia, NL; Medvedeva, TIu; Miroshnichenko, NG; Okonova, EB; Plieva, OK; Rudenko, TE; Shonichev, DG; Shvetsov, MIu; Stavrovskaia, EV | 1 |
9 review(s) available for valsartan and Chronic Kidney Failure
| Article | Year |
|---|---|
[Neprilysin inhibition and chronic kidney disease].
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan | 2015 |
Reduction of proteinuria with angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cytoprotection; Humans; Hypertension; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Models, Biological; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
Blockade of the renin-angiotensin system: better late than never.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Complications; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Peritoneal Dialysis, Continuous Ambulatory; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2004 |
[Molecular mechanisms underlying proteinuria reduction and protection of nephrin and podocytes by ARB].
Topics: Actinin; Actins; Adaptor Proteins, Signal Transducing; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cytoskeletal Proteins; Humans; Intracellular Signaling Peptides and Proteins; Kidney Failure, Chronic; Membrane Proteins; Podocytes; Proteins; Proteinuria; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2006 |
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium; Calcium Channel Blockers; Humans; Kidney Failure, Chronic; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Valine; Valsartan | 2001 |
22 trial(s) available for valsartan and Chronic Kidney Failure
| Article | Year |
|---|---|
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cholesterol, HDL; Double-Blind Method; Female; Humans; Inflammation Mediators; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Ramipril; Renal Dialysis; Tennessee; Time Factors; Treatment Outcome; Valsartan | 2018 |
Short-term administration of an angiotensin II receptor blocker in patients with long-term hemodialysis patients improves insulin resistance.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Glucose; Female; Humans; Insulin Resistance; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradykinin; Cell Line; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ramipril; Renal Dialysis; Valsartan | 2015 |
Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Creatinine; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Valsartan | 2017 |
Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Female; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Female; Humans; Incidence; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2008 |
Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptides; Peritoneal Dialysis, Continuous Ambulatory; Pulse; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Brachial Artery; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Prognosis; Prospective Studies; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vascular Stiffness; Vasodilation | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Coagulation; CD40 Ligand; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Hemodynamics; Humans; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Ramipril; Renal Dialysis; Renin; Tetrazoles; Valine; Valsartan | 2012 |
31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients.
Topics: Adult; Angiotensin Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Magnetic Resonance Spectroscopy; Male; Middle Aged; Phosphates; Tetrazoles; Valine; Valsartan | 2012 |
Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; Drug Chronotherapy; Echocardiography; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Creatinine; Female; Humans; Hypertension; Japan; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Cavity; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Proteinuria; Retrospective Studies; Tetrazoles; Urine; Valine; Valsartan | 2004 |
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Topics: Adult; Aged; Antihypertensive Agents; Cross-Over Studies; Diet, Sodium-Restricted; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Proteinuria; Ramipril; Reference Values; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Urea Nitrogen; Creatinine; Erythropoietin; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Kidney Failure, Chronic; Male; Middle Aged; Potassium; Tetrazoles; Uric Acid; Valine; Valsartan | 2005 |
Blockade of renin-angiotensin system reduces QT dispersion and improves intracellular Ca/Mg status in hemodialysis patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium; Cilazapril; Female; Heart Rate; Humans; In Vitro Techniques; Kidney Failure, Chronic; Magnesium; Male; Middle Aged; Renal Dialysis; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2006 |
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Female; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Methylation; Middle Aged; Oxidative Stress; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2006 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Female; Glomerular Filtration Rate; Hemorheology; Humans; Insulin Resistance; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proteinuria; Ramipril; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2007 |
Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
Topics: Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Creatinine; Dextrans; Double-Blind Method; Erythrocyte Count; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Inulin; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Molecular Weight; p-Aminohippuric Acid; Particle Size; Potassium; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 1998 |
Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Renal Circulation; Tetrazoles; Valine; Valsartan | 1999 |
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Creatinine; Drug Combinations; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Pilot Projects; Potassium; Proteinuria; Safety; Tetrazoles; Valine; Valsartan | 2000 |
[Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Follow-Up Studies; Glomerulonephritis; Humans; Hypertension; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
11 other study(ies) available for valsartan and Chronic Kidney Failure
| Article | Year |
|---|---|
Simultaneous determination and pharmacokinetics study of valsartan, sacubitril and its major metabolite in human plasma, urine and peritoneal dialysis fluid in patients with end-stage renal disease by UPLC-MS/MS.
Topics: Aminobutyrates; Biphenyl Compounds; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Kidney Failure, Chronic; Peritoneal Dialysis; Tandem Mass Spectrometry; Valsartan | 2022 |
Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Stroke Volume; Valsartan | 2022 |
Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i.
Topics: Female; Heart Failure; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice.
Topics: Angiopoietin-Like Protein 3; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Failure, Chronic; Mice; Podocytes; Reactive Oxygen Species; Streptozocin; Valsartan | 2023 |
Sacubitril/valsartan in heart failure and end-stage renal insufficiency.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Tetrazoles; Valsartan | 2019 |
Effect of sacubitril-valsartan on cardiac function in hemodialysis patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Pilot Projects; Renal Dialysis; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Valsartan Alleviates Insulin Resistance in Skeletal Muscle of Chronic Renal Failure Rats.
Topics: Angiotensin II; Animals; Cell Line; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Kidney Failure, Chronic; Male; Muscle, Skeletal; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Valsartan | 2018 |
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Apolipoproteins E; Bezafibrate; Child; Child, Preschool; Enalapril; Female; Hematuria; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Failure, Chronic; Kidney Glomerulus; Nephrotic Syndrome; Probucol; Tetrazoles; Valine; Valsartan | 2009 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2004 |
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Blotting, Western; Creatinine; Disease Models, Animal; DNA; Heart Failure; Immunohistochemistry; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2007 |
Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Chemokine CCL2; Chemotaxis, Leukocyte; Gene Expression; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Macrophages; Monocytes; Nephrosclerosis; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2000 |